Cargando…
Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework
IMPORTANCE: A National Institute on Aging–Alzheimer’s Association (NIA-AA) workgroup recently published a research framework in which Alzheimer disease is defined by neuropathologic or biomarker evidence of β-amyloid plaques and tau tangles and not by clinical symptoms. OBJECTIVES: To estimate the s...
Autores principales: | Jack, Clifford R., Therneau, Terry M., Weigand, Stephen D., Wiste, Heather J., Knopman, David S., Vemuri, Prashanthi, Lowe, Val J., Mielke, Michelle M., Roberts, Rosebud O., Machulda, Mary M., Graff-Radford, Jonathan, Jones, David T., Schwarz, Christopher G., Gunter, Jeffrey L., Senjem, Matthew L., Rocca, Walter A., Petersen, Ronald C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632154/ https://www.ncbi.nlm.nih.gov/pubmed/31305929 http://dx.doi.org/10.1001/jamaneurol.2019.1971 |
Ejemplares similares
-
Longitudinal tau PET in ageing and Alzheimer’s disease
por: Jack, Clifford R, et al.
Publicado: (2018) -
Age and sex specific prevalences of cerebral β-amyloidosis, tauopathy and neurodegeneration among clinically normal individuals aged 50-95 years: a cross-sectional study
por: Jack, Clifford R., et al.
Publicado: (2017) -
Rates of transition between amyloid and neurodegeneration biomarker states and to dementia among non-demented individuals: a population-based cohort study
por: Jack, Clifford R., et al.
Publicado: (2015) -
NIA‐AA Alzheimer's Disease Framework: Clinical Characterization of Stages
por: Petersen, Ronald C., et al.
Publicado: (2021) -
Associations of quantitative susceptibility mapping with Alzheimer’s disease clinical and imaging markers
por: Cogswell, Petrice M., et al.
Publicado: (2020)